Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A clinical practice guideline (CPG) from the American Society of Plastic Surgeons recommended not to use drains in breast reduction. This CPG was based on 3 randomized controlled trials (RCTs). The objective of this review was to double-check the methodological quality of the 3 RCTs. These RCTs were critically appraised using: (1) the "User's Guide to the Surgical Literature" checklist to critically appraise the methodological quality, (2) the CONSORT guidelines for reporting quality, and (3) the Cochrane risk-of-bias tool 2 (RoB 2) for risk of bias. Weaknesses were identified in all assessments for the 3 RCTs. Items with the poorest adherence in the "User's Guide" included: "Were patients stratified?," "Was follow-up complete?," and "Were all clinically important outcomes considered?" The overall adherence to the CONSORT reporting checklist across all 3 studies was moderate with 40.0%, 62.1%, and 48.3% adherence. All 3 RCTs had a similar low to moderate risk of bias, with no areas with a high risk of bias. None of the studies took into consideration a single critical outcome (such as major hematoma) and the outcome's minimally important difference as the basis for the sample size and power calculation of the study. All 3 RCTs additionally lacked clear reporting of treatment effect sizes or precision of estimates. Our re-examination of the evidence questions the recommendation of the CPG. We believe that the recommendation should have been: "We remain uncertain whether drains in breast reduction have a salutary effect." As such, we recommend that a methodologically robust RCT be conducted to resolve the question of whether drains should be used in breast reduction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11474604PMC
http://dx.doi.org/10.1093/asj/sjae116DOI Listing

Publication Analysis

Top Keywords

drains breast
16
breast reduction
16
risk bias
12
methodological quality
8
rcts
6
drains
4
reduction
4
reduction good
4
good recommendation
4
recommendation them?
4

Similar Publications

Radiation therapy (RT) plays important roles in cancer treatment, and the efficacy of RT depends on the abscopal effect, which results in the regression of distant and untreated tumors through localized irradiation of a single tumor lesion. This effect is mediated by effector tumor antigen-specific T cells (ETASTs) activated by RT. Monitoring the radiation-induced changes in ETASTs can be used to predict the abscopal effect.

View Article and Find Full Text PDF

Background: Patient electronic communication (PEC) via secure messaging is important for patient engagement. While PEC has been studied in primary care, data on surgical specialties, particularly plastic surgery, remain limited.

Objectives: This study assessed the volume and content of post-discharge PECs among patients undergoing post-mastectomy autologous breast reconstruction.

View Article and Find Full Text PDF

Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administration.

Cytotherapy

August 2025

Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA; Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, USA; Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Electroni

Background Aims: Cancers of many different tissue origins can metastasize to the pleura, a space with a unique immune environment that predisposes to aggressive tumor behavior and the development of effusions, an exudative leakage of serous fluid accompanied by an immune infiltrate. Effusions are drained therapeutically to relieve dyspnea, often several times per week. Characteristically, they contain 50-1000 × 10 viable pleural T cells (PITs), which can be reliably activated and expanded in culture, making them an ideal source for generation of a cellular therapeutic.

View Article and Find Full Text PDF

Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer.

Dev Cell

August 2025

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China; State Key Laboratory of Oncology in South China, Sun Yat

Tumor-antigen-specific CD8 T cells (CTLs) are the main effector immunocytes in anti-tumor immunity, but their systemic deployment against cancer metastasis remains uncharacterized. Here, we found that the abundance of tumor-specific CD103CD8 T cells in the tumor-draining lymph nodes (TDLNs) was associated with improved lung-metastasis-free survival in breast cancer patients. In mouse cancer models, CD103CD8 T cells were primed in TDLNs and recruited to the lungs via C-C motif chemokine ligand 5/receptor 9 (CCL25/CCR9) signaling to inhibit metastasis through antigen-specific immunity.

View Article and Find Full Text PDF

Background: Breast cancer treatment-related lymphedema (BCRL) is a chronic progressive morbidity for which a definitive cure has not yet been achieved. Since axillary lymph node dissection (ALND) is the main risk factor, we have studied the pattern of lymphatic drainage and subclinical lymphedema progression with ICG lymphography (ICG-L) after ALND as a part of our strategy to prevent BCRL.

Methods: This study was a prospective cohort of breast cancer patients who underwent ALND between October 2022 and August 2024.

View Article and Find Full Text PDF